<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110434</url>
  </required_header>
  <id_info>
    <org_study_id>R01DA026778</org_study_id>
    <secondary_id>R01DA026778</secondary_id>
    <nct_id>NCT01110434</nct_id>
  </id_info>
  <brief_title>Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents</brief_title>
  <official_title>Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabis use is a significant public health concern that disproportionately affect youth.&#xD;
      Although promising psychosocial interventions are being developed, most youth do not benefit&#xD;
      from these interventions alone. Given the clinical demand for effective treatments, the&#xD;
      National Institute on Drug Abuse (NIDA) identified the critical need for data on the&#xD;
      tolerability and potential efficacy of medications in adolescents. The purpose of this&#xD;
      two-year study is to test if and how topiramate, a medication under intense study for&#xD;
      treating several drugs of abuse, reduces cannabis use among teenagers. To this end, the&#xD;
      investigators will randomize 56 nontreatment-seeking regular cannabis users (15 or 20 years&#xD;
      old) to receive topiramate or placebo for 6 weeks. Youth will monitor their cannabis use for&#xD;
      the 6-week period using handheld electronic diaries and complete assessments of reactivity to&#xD;
      cannabis-related cues.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cannabis Use</measure>
    <time_frame>Weeks 1-6</time_frame>
    <description>Frequency of Cannabis Use (Percent Use Days Per Week)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of Cannabis Use</measure>
    <time_frame>Weeks 1-6</time_frame>
    <description>Total Grams of Cannabis Use Per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Cannabis Use Per Use Day</measure>
    <time_frame>Weeks 1-6</time_frame>
    <description>Average Grams of Cannabis Used Per Use Day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Cannabis Abuse</condition>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate (200 mg daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Topiramate (200 mg daily)</description>
    <arm_group_label>Topiramate</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (daily)</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  15 to 20 years old (inclusive)&#xD;
&#xD;
          -  Non-treatment seeking for cannabis abuse or dependence&#xD;
&#xD;
          -  Able to read English, understand their rights as provided by the informed consent&#xD;
             process, and be willing to sign an informed consent form to participant in the study&#xD;
&#xD;
          -  If younger than 18 years old, informed consent from a parent or legal guardian is&#xD;
             required&#xD;
&#xD;
          -  Used cannabis at least 2 days per week during the past 30 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment seeking or a recent history of treatment for cannabis abuse or dependence&#xD;
&#xD;
          -  Endorses a current commitment to stop using cannabis&#xD;
&#xD;
          -  Clinically significant physical abnormalities as indicated by physical exam,&#xD;
             hematological assessment, bilirubin concentration or urinalysis&#xD;
&#xD;
          -  History of renal impairment, renal stones, seizures, or unstable hypertension&#xD;
&#xD;
          -  Underweight (i.e., less than the 5th percentile) or overweight (equal to or greater&#xD;
             than the 95th percentile), as determined by the Body Mass Index&#xD;
&#xD;
          -  Positive urine toxicology screen for narcotics, amphetamines, or sedative hypnotics or&#xD;
             self-reported drug use, other than cannabis, alcohol or nicotine, in the past 30 days&#xD;
&#xD;
          -  Pregnant, nursing, or refusal to use reliable barrier method of birth control (e.g.,&#xD;
             condom), if female&#xD;
&#xD;
          -  Took a psychotropic medication in the past 30 days&#xD;
&#xD;
          -  Taking medications with a potential effect on cannabis use or a carbonic anhydrase&#xD;
             inhibitor&#xD;
&#xD;
          -  Suicidal&#xD;
&#xD;
          -  A current DSM-IV-TR Axis I diagnosis other than attention- deficit/hyperactivity&#xD;
             disorder or a disruptive behavior disorder&#xD;
&#xD;
          -  A current substance use disorder other than a cannabis, alcohol, and nicotine use&#xD;
             disorders&#xD;
&#xD;
          -  Significant alcohol withdrawal symptoms&#xD;
&#xD;
          -  Known sensitivity to topiramate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Miranda, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University, Center for Alcohol and Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>August 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Robert Miranda</investigator_full_name>
    <investigator_title>Associate Professor (Research)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Topiramate</title>
          <description>Topiramate (200 mg daily)&#xD;
Topiramate: Topiramate (200 mg daily)</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo (daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topiramate</title>
          <description>Topiramate (200 mg daily)&#xD;
Topiramate: Topiramate (200 mg daily)</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo (daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.30" spread="2.03"/>
                    <measurement group_id="B2" value="18.81" spread="2.08"/>
                    <measurement group_id="B3" value="19.71" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cannabis Use</title>
        <description>Frequency of Cannabis Use (Percent Use Days Per Week)</description>
        <time_frame>Weeks 1-6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg daily)&#xD;
Topiramate: Topiramate (200 mg daily)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo (daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Cannabis Use</title>
          <description>Frequency of Cannabis Use (Percent Use Days Per Week)</description>
          <units>Percentage of use days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.89" spread="32.35"/>
                    <measurement group_id="O2" value="63.10" spread="34.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of Cannabis Use</title>
        <description>Total Grams of Cannabis Use Per week</description>
        <time_frame>Weeks 1-6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg daily)&#xD;
Topiramate: Topiramate (200 mg daily)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo (daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Quantity of Cannabis Use</title>
          <description>Total Grams of Cannabis Use Per week</description>
          <units>Grams Per Week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="2.11"/>
                    <measurement group_id="O2" value="2.85" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Cannabis Use Per Use Day</title>
        <description>Average Grams of Cannabis Used Per Use Day</description>
        <time_frame>Weeks 1-6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topiramate</title>
            <description>Topiramate (200 mg daily)&#xD;
Topiramate: Topiramate (200 mg daily)</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo (daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Cannabis Use Per Use Day</title>
          <description>Average Grams of Cannabis Used Per Use Day</description>
          <units>Average Grams Per Use Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.32"/>
                    <measurement group_id="O2" value="0.60" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected during the 6-week medication (or placebo pill) period.</time_frame>
      <desc>We followed the same definition as clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>Topiramate</title>
          <description>Topiramate (200 mg daily)&#xD;
Topiramate: Topiramate (200 mg daily)</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo (daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Changes in Vision</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Pain, Cramps</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Cough, Cold Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Parasthesias</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Runny Nose, Sinus Problems, Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Decrease in Appetite</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Difficulty with Coordination or Balance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Difficulty with Memory</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Difficulty with Concentration or Attention</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Word Finding Difficulties</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Slow Thinking or Reactions</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Drowsiness or Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Miranda</name_or_title>
      <organization>Brown University</organization>
      <phone>401.863.6658</phone>
      <email>Robert_Miranda_Jr@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

